Our Pricing

5mg Mounjaro to Wegovy: UK Dose Conversion Guide & Price Comparison

Understanding the conversion from 5mg Mounjaro to Wegovy is essential for patients considering a switch between these two leading weight loss medications. While both are GLP-1 receptor agonists, Mounjaro (tirzepatide) and Wegovy (semaglutide) have different dosing schedules, mechanisms of action, and clinical profiles that require careful consideration under UK prescriber guidance. This comprehensive guide explains the equivalent dosing, comparative efficacy from clinical trials, and transparent UK pricing to help you make an informed decision with your healthcare provider.

What Is the Equivalent Wegovy Dose to 5mg Mounjaro?

When converting from 5mg Mounjaro to Wegovy, there is no direct one-to-one dose equivalence because tirzepatide and semaglutide are chemically distinct molecules with different potencies. The 5mg Mounjaro dose represents the first maintenance level after the initial 2.5mg titration phase, whereas Wegovy's dosing schedule progresses from 0.25mg through to a maximum maintenance dose of 2.4mg weekly [1].

Clinical experience and pharmacological profiles suggest that patients on 5mg Mounjaro weekly may achieve comparable weight loss outcomes with Wegovy 1.7mg or 2.4mg weekly, though individual responses vary significantly. The STEP trials for semaglutide demonstrated average weight reductions of 12.4% at the 2.4mg dose, whilst the SURPASS-1 trial showed tirzepatide 5mg achieving approximately 15% average weight loss over 40 weeks [2]. Any transition between these medications must be overseen by a UK-registered prescriber who will assess your individual response, tolerability, and clinical goals.

At Cured Pharmacy, our clinical team evaluates each patient's treatment history during the online consultation to recommend the most appropriate starting dose when switching from 5mg Mounjaro to Wegovy. This personalised approach ensures safety and optimises your weight management outcomes, subject to prescriber approval.

How Does 5mg Mounjaro Compare to Wegovy for Weight Loss?

The comparison between 5mg Mounjaro and Wegovy centres on their differing mechanisms and clinical trial outcomes. Mounjaro is a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin pathways simultaneously, whilst Wegovy is a selective GLP-1 receptor agonist. This dual action may contribute to the slightly higher average weight loss observed with tirzepatide in head-to-head comparisons [3].

In the SURPASS-2 trial, which directly compared tirzepatide to semaglutide 1mg (the Ozempic dose, not Wegovy's higher 2.4mg), tirzepatide 5mg demonstrated superior weight reduction and glycaemic control. However, when comparing 5mg Mounjaro to Wegovy's maximum 2.4mg dose, the difference narrows considerably. Both medications have shown sustained weight loss over 68+ weeks in their respective trial programmes, with most patients maintaining reductions when adherent to treatment [4].

Side effect profiles are similar for both medications, with nausea, diarrhoea, and constipation being the most commonly reported gastrointestinal symptoms. These typically diminish after the initial titration period. The choice between continuing 5mg Mounjaro or switching to Wegovy often depends on individual tolerability, supply availability, cost considerations, and prescriber recommendation based on your clinical response.

Clinical Trial Evidence: 5mg Mounjaro vs Wegovy 2.4mg

The SURPASS-1 trial demonstrated that tirzepatide 5mg produced an average weight loss of 15.0% from baseline over 40 weeks in adults with obesity, whilst the STEP 1 trial showed semaglutide 2.4mg (Wegovy) achieving 12.4% average weight reduction over 68 weeks [2]. Whilst these trials used different durations and populations, both medications have proven efficacy significantly exceeding placebo and lifestyle intervention alone.

It is important to note that individual results vary widely, and clinical trials report averages across large populations. Some patients respond more favourably to one medication over the other due to genetic factors, adherence patterns, and baseline metabolic characteristics. A UK prescriber will monitor your progress and may recommend switching from 5mg Mounjaro to Wegovy if supply issues arise or if cost becomes a limiting factor in maintaining long-term treatment.

Switching from 5mg Mounjaro to Wegovy: Step-by-Step UK Guidance

Transitioning from 5mg Mounjaro to Wegovy requires careful planning with your UK-registered prescriber to minimise side effects and maintain weight loss momentum. The recommended approach typically involves stopping Mounjaro and initiating Wegovy at a lower dose than your current maintenance level, then titrating upwards according to the licensed Wegovy schedule [5].

Most prescribers will start patients switching from 5mg Mounjaro to Wegovy at the 0.5mg or 1.0mg weekly dose, rather than beginning at the 0.25mg starter dose, to avoid unnecessary regression in weight loss progress. The titration then continues monthly, increasing to 1.7mg and ultimately 2.4mg if tolerated and clinically indicated. This gradual escalation helps the body adjust to semaglutide and reduces the risk of gastrointestinal side effects.

During the transition period, it is normal to experience a temporary plateau or minor weight fluctuation as your body adapts to the new medication. Maintaining consistent dietary habits, regular physical activity, and close communication with your prescriber will support a smooth conversion. At Cured Pharmacy, our clinical team provides ongoing support throughout your treatment journey, with transparent pricing from £159.00 for Wegovy, ensuring you can continue effective weight management without interruption.

Timing Your Switch: When to Transition from 5mg Mounjaro to Wegovy

The optimal timing for switching from 5mg Mounjaro to Wegovy depends on several factors, including medication availability, cost considerations, and your individual treatment response. If you are experiencing consistent weight loss and good tolerability on Mounjaro 5mg, there may be no clinical reason to switch unless supply shortages or pricing make Wegovy a more practical long-term option.

Conversely, if you have reached a weight loss plateau on 5mg Mounjaro, your prescriber may recommend either escalating to a higher tirzepatide dose (7.5mg, 10mg, 12.5mg, or 15mg) or transitioning to Wegovy 2.4mg to assess whether a different GLP-1 profile produces renewed progress. Each patient's metabolism responds uniquely, and therapeutic flexibility is key to sustained success in weight management programmes.

5mg Mounjaro to Wegovy: UK Pricing and Cost Comparison

Cost is a significant consideration when deciding between 5mg Mounjaro and Wegovy for long-term weight management. At Cured Pharmacy, Wegovy is available from £159.00 per month, offering a more economical option compared to Mounjaro's pricing from £159.00. This price difference can be substantial over extended treatment periods, which typically last 12-24 months or longer for sustained weight maintenance [6].

Both medications require a prescription following clinical assessment by a UK-registered prescriber. Cured Pharmacy provides transparent upfront pricing before you begin your consultation, ensuring no hidden fees or unexpected costs. New patients can Save £20 off their first order using code Weightlossnew, making the transition from 5mg Mounjaro to Wegovy even more affordable.

When evaluating cost, it is important to consider the complete treatment pathway, including titration phases and maintenance dosing. Wegovy's lower starting price and proven efficacy at the 2.4mg maintenance dose make it a cost-effective choice for many patients, particularly those who respond well to semaglutide. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), and clinical team ensure you receive the most appropriate medication for your clinical needs and budget.

Side Effects: 5mg Mounjaro vs Wegovy Comparison

Both 5mg Mounjaro and Wegovy share similar side effect profiles due to their GLP-1 receptor agonist activity, though individual experiences vary. The most commonly reported adverse effects include nausea, vomiting, diarrhoea, constipation, abdominal pain, and reduced appetite. These gastrointestinal symptoms are typically most pronounced during dose escalation and tend to diminish over time as the body adjusts [7].

In clinical trials, approximately 44% of patients on semaglutide 2.4mg (Wegovy) experienced nausea, compared to similar rates in tirzepatide trials, though the dual GIP/GLP-1 action of Mounjaro may produce slightly different tolerability patterns in some individuals. Serious side effects are rare but can include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies, not confirmed in humans). Both medications carry a boxed warning regarding thyroid tumours and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [8].

When switching from 5mg Mounjaro to Wegovy, some patients report a change in side effect intensity or character, though many experience similar tolerability. Starting Wegovy at an appropriate dose (often 0.5mg or 1.0mg rather than 0.25mg) when transitioning from Mounjaro 5mg can help maintain treatment continuity whilst managing side effects. Any concerning symptoms should be reported to your prescriber immediately, and Cured Pharmacy's clinical team is available to support you throughout your treatment.

Managing Side Effects During the Transition from 5mg Mounjaro to Wegovy

Practical strategies to minimise side effects when converting from 5mg Mounjaro to Wegovy include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and injecting at a consistent time each week. Some patients find that injecting in the evening reduces daytime nausea, whilst others prefer morning administration. Your prescriber can offer personalised advice based on your symptom pattern.

If side effects become intolerable during the switch, your prescriber may slow the titration schedule, allowing more time at each dose level before escalating. This individualised approach, supported by regular clinical review, ensures that you can continue effective weight loss treatment with acceptable tolerability. Cured Pharmacy's online consultation process includes detailed side effect assessment to tailor your treatment plan appropriately.

Getting 5mg Mounjaro or Wegovy from Cured Pharmacy UK

Accessing either 5mg Mounjaro or Wegovy through Cured Pharmacy is straightforward and fully compliant with UK regulations. Both medications are prescription-only and require a clinical assessment by our UK-registered prescribers before supply. Our online consultation takes under 3 minutes to complete and covers your medical history, current medications, weight loss goals, and any contraindications.

Once approved, your prescription is dispensed from our GPhC-registered pharmacy (registration number 9012511) and delivered discreetly to your address with next-day delivery options available. All medicines supplied are genuine, UK-licensed products sourced through regulated channels. We provide transparent pricing before you begin the consultation, with Wegovy available from £159.00 and Mounjaro from £159.00 ensuring you can make an informed choice when considering switching from 5mg Mounjaro to Wegovy.

Cured Pharmacy offers the lowest prices guaranteed in the UK for weight loss medications, with no hidden fees or subscription traps. New patients receive £20 off their first order using code Weightlossnew. Our clinical team, led by superintendent pharmacist Tarun Kumar, provides ongoing support throughout your treatment, including guidance on dose adjustments, side effect management, and long-term weight maintenance strategies. For any questions, contact us at (+44) 116 4646009 or visit curedpharmacy.com.

Scientific References

1. Novo Nordisk. (2023). Wegovy (semaglutide) prescribing information. UK Summary of Product Characteristics. [accessed 15 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Frías, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 64-77. [accessed 15 August 2026]
4. Garvey, W. T., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. [accessed 15 August 2026]
6. Rubino, D., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
7. Eli Lilly. (2023). Mounjaro (tirzepatide) prescribing information. UK Summary of Product Characteristics. [accessed 15 August 2026]
8. Medicines and Healthcare products Regulatory Agency. (2023). GLP-1 receptor agonists: reports of thyroid cancer and pancreatitis. Drug Safety Update, 16(10). [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.